Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Price Target at $32.60

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been assigned an average recommendation of “Buy” from the five research firms that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $32.60.

Several equities research analysts have weighed in on AARD shares. Wall Street Zen downgraded Aardvark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. HC Wainwright started coverage on Aardvark Therapeutics in a report on Monday, June 30th. They issued a “buy” rating and a $40.00 price target for the company. Bank of America lowered their price target on Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, August 28th. Finally, Royal Bank Of Canada lowered their price target on Aardvark Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, August 14th.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD opened at $9.95 on Friday. Aardvark Therapeutics has a 1-year low of $4.88 and a 1-year high of $19.58. The business has a fifty day moving average price of $10.88 and a 200 day moving average price of $10.51.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.14).

Insider Activity

In other news, CEO Tien-Li Lee acquired 5,000 shares of Aardvark Therapeutics stock in a transaction dated Friday, September 12th. The stock was purchased at an average cost of $8.50 per share, for a total transaction of $42,500.00. Following the completion of the purchase, the chief executive officer directly owned 1,533,384 shares in the company, valued at $13,033,764. This trade represents a 0.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Nelson Sun acquired 6,000 shares of Aardvark Therapeutics stock in a transaction dated Tuesday, September 9th. The stock was purchased at an average price of $8.07 per share, with a total value of $48,420.00. Following the completion of the purchase, the chief financial officer owned 105,484 shares of the company’s stock, valued at approximately $851,255.88. The trade was a 6.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 26,000 shares of company stock valued at $209,030.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Aardvark Therapeutics in the second quarter worth about $42,000. Walleye Capital LLC purchased a new position in shares of Aardvark Therapeutics in the first quarter worth about $88,000. New York State Common Retirement Fund purchased a new position in Aardvark Therapeutics during the second quarter valued at approximately $99,000. Bank of America Corp DE raised its position in Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in Aardvark Therapeutics during the first quarter valued at approximately $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.